Monopar Therapeutics (NASDAQ:MNPR) Announces Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Monopar Therapeutics (NASDAQ:MNPR) issued its earnings results on Friday. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13), reports.

Monopar Therapeutics Stock Performance

Shares of NASDAQ MNPR traded up $0.85 during midday trading on Friday, reaching $55.41. The stock had a trading volume of 118,052 shares, compared to its average volume of 250,472. Monopar Therapeutics has a twelve month low of $26.06 and a twelve month high of $105.00. The company’s 50 day moving average price is $59.94 and its 200 day moving average price is $70.49. The firm has a market cap of $370.31 million, a price-to-earnings ratio of -16.11 and a beta of 1.58.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MNPR. BTIG Research reaffirmed a “buy” rating and issued a $104.00 price target on shares of Monopar Therapeutics in a research note on Monday, February 23rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, January 21st. Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Chardan Capital reaffirmed a “buy” rating and set a $100.00 price target on shares of Monopar Therapeutics in a report on Thursday, January 29th. Finally, Morgan Stanley started coverage on shares of Monopar Therapeutics in a research report on Friday, January 9th. They set an “overweight” rating and a $115.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $107.00.

Institutional Trading of Monopar Therapeutics

Several hedge funds have recently modified their holdings of MNPR. Russell Investments Group Ltd. bought a new position in shares of Monopar Therapeutics during the 3rd quarter worth about $28,000. BNP Paribas Financial Markets raised its stake in Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after buying an additional 349 shares during the period. Meeder Asset Management Inc. bought a new position in Monopar Therapeutics in the fourth quarter worth approximately $65,000. JPMorgan Chase & Co. boosted its holdings in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after acquiring an additional 1,821 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Monopar Therapeutics in the second quarter valued at approximately $80,000. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.